Immunomedics (IMMU) - moderated Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

Recommended by:

To: sysiphus who wrote (38523)	1/9/2017 8:37:13 AM
From: li3511	9 Recommendations of 63307

> IMMU's proposed Directors don't seem as qualified / appropriate to me as do venBio's. I'm trying to get an initial read on that, and I suspect you're right. Jason Aryeh, the new Vice Chairman, is Chairman of the Board of Novelion Therapeutics, Inc. (NASDAQ:NVLN). If you've never heard of them, you're not alone. it's a small Canadian company (Vancouver) with annual sales (2016 and 2017) of about $160 million, and about $100 million in cash. globenewswire.com Within the last month, they had a 1:5 reverse stock split. globenewswire.com This isn't an indicator of a healthy, well managed company. Re: Geoffrey Cox: "[H]e served as interim CEO of QLT Inc. (NASDAQ:NVLN), a publicly traded ophthalmology company." Hmmm... Anyone notice that Novelion and QLT are the same company? In looking for new friends, David and Cindy are digging pretty deep.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next